Back to discover
Disease

Borderline Personality Disorder

Late-stage therapeutic developmentEmerging research
MeSHBorderline Personality Disorder
2
Publications
17
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

A Phase Ib, Multicentre, Randomised, Double Blind, Placebo Controlled, 2 Sequence Crossover Trial to Evaluate the Effects of BI 3031185 on Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Clinical trial2026-08-10Status changed to Completed · ClinicalTrials.gov

A Phase Ib, Multicentre, Randomised, Double Blind, Placebo Controlled, 2 Sequence Crossover Trial to Evaluate the Effects of BI 3031185 on Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Clinical trial2026-07-28Status changed to Active, not recruiting · ClinicalTrials.gov

Emotion dysregulation in bipolar disorder compared to other mental illnesses: a systematic review and meta-analysis.

Research2023-10-16Psychological medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q2 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones5View
Results expected 3
Recently completed 2
Industry & Market2View
Activity timeline7

Clinical trials

14 sponsors · 1 new · 1 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
17
All trials
5
Active
8
Late-stage
6
Completed
Late-stage studies

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder

Phase 2/3 · Completed · Otsuka Pharmaceutical Development & Commercialization, Inc.

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change

Phase 4 · Completed · New York State Psychiatric Institute

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Phase 3 · Completed · Mood and Anxiety Research, Inc

Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence

Phase 3 · Withdrawn · Elizabeth Ralevski

Seroquel XR for the Management of Borderline Personality Disorder (BPD)

Phase 3 · Completed · University of Minnesota

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder

Phase 4 · Completed · New York State Psychiatric Institute
Recruiting

The Effects of MDMA (3,4-methylenedioxymethamphetamine) in Social Cognition in Borderline Personality Disorder

Phase 2 · Recruiting · Yale University

A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder

Phase 2 · Recruiting · The Alfred

A Multi-center, Patient-blinded and Investigator-blinded, Randomized, Parallel-group, Superiority Study to Compare the Efficacy of Four Sessions of Amygdala fMRI-BOLD Neurofeedback With Yoked Sham-control Neurofeedback in the Treatment of Dysregulated Affect in Borderline Personality Disorder

Phase 1/2 · Recruiting · Central Institute of Mental Health, Mannheim

A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)

Phase 1/2 · Recruiting · Mclean Hospital
Recently completed

A Phase Ib, Multicentre, Randomised, Double Blind, Placebo Controlled, 2 Sequence Crossover Trial to Evaluate the Effects of BI 3031185 on Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Phase 1 · Completed · Boehringer Ingelheim

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder

Phase 2/3 · Completed · Otsuka Pharmaceutical Development & Commercialization, Inc.

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change

Phase 4 · Completed · New York State Psychiatric Institute

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

Phase 3 · Completed · Mood and Anxiety Research, Inc

Seroquel XR for the Management of Borderline Personality Disorder (BPD)

Phase 3 · Completed · University of Minnesota

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder

Phase 4 · Completed · New York State Psychiatric Institute

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2006–2023
Major themes6
  • Attention Deficit Disorder with Hyperactivity1
  • Bipolar Disorder1
  • Borderline Personality Disorder1
  • Emotional Regulation1
  • Major Depressive Disorder1
  • Suicide Prevention1
Leading journals2
  • Archives of general psychiatry1
  • Psychological medicine1
Leading researchers8
  • Anmella G1
  • Brown MZ1
  • Comtois KA1
  • de Bartolomeis A1
  • De Prisco M1
  • Fico G1
  • Fornaro M1
  • Gallop RJ1
Affiliations (unnormalised)6
  • Behavioral Research and Therapy Clinics1
  • Centre for Psychiatric Research and Education1
  • Early Psychosis: Interventions and Clinical-Detection (EPIC) Lab1
  • Hospìtal Clinic de Barcelona. c. Villarroel1
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)1
  • Institute of Neurosciences (UBNeuro)1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)

Identifiers
MeSHBorderline Personality Disorder
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.